- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07857070
Newborn Brain Assessment - CergenX Wave (NBT)
Determining Grade of Neonatal Encephalopathy - Agreement Between the Modified Sarnat Examination and Automated AI Assessment of Newborn Brain Function Using Wave Software
In this study we want to assess how a newly developed software device called CergenX Wave compares to the modified Sarnat examination, performed by the neonatology team . The Wave software algorithm (which is a set of rules used by the computer) analyses EEG activity, using four electrodes placed on the neonate's scalp.
A portable EEG machine records the EEG activity and a tablet will send this information to the cloud where the device analyses the data, as shown in the figure below. The EEG activity the Wave device evaluates will not be available to either the research or clinical team during the investigation but once the recording is completed the device will display a code on screen for the research team to confirm completion.
The results will not be visible to either the researchers or the clinical team therefore will not in any way influence the care of the neonate. This is a regulated observational investigation to compare how the software performs against the current standard of care, a standardised neurological examination.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Brian Walsh, Neonatologist
- Telefonnummer: +353214920525
- E-Mail: brianhenry.walsh@ucc.ie
Studienorte
-
-
Cork
-
Cork, Cork, Irland
- Rekrutierung
- Cork University Maternity Hospital
-
Kontakt:
- Aisling Fanning
- Telefonnummer: +353214920525
- E-Mail: aisling.fanning1@hse.ie
-
-
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75235
- Noch keine Rekrutierung
- University of Texas Southwestern Medical Center
-
Kontakt:
- Lina Chalak
- Telefonnummer: 214-648-3060
- E-Mail: Lina.Chalak@UTSouthwestern.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Infants at high-risk of Neonatal Encephalopathy
Beschreibung
Inclusion Criteria:
-
Infants born at ≥36+0 weeks gestational age
-
Informed consent obtained AND
-
A pH of ≤7.0 or base deficit ≥16 (on cord or 1st infant blood gas at < 1 hour of life) OR
-
a) A pH of 7.01-7.15 or base deficit of 10-15.9 (on cord or 1st infant blood gas at < 1 hour of life) WITH b) at least one of the following:
-
An APGAR score ≤5 at 10 minutes OR
-
Prolonged resuscitation (infant receiving IPPV at ≥10 minutes of life) OR
-
An acute perinatal event:
- Abnormal CTG (variable/late foetal HR decelerations)
- Foetal bradycardia
- Prolapsed/ruptured/tight nuchal cord
- Shoulder dystocia
- Uterine rupture
- Maternal haemorrhage/placental abruption
- Maternal trauma (e.g. vehicle accident)
- Mother received CPR
-
Exclusion Criteria:
- Infants < 36 weeks gestation
- No parental/guardian consent
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: CASE_ONLY
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Neonates
Neonates at risk of Neonatal Encephalopathy |
The amplifier is used to acquire and transmit the EEG to the CergenX Wave software that is installed in a COTS computer.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Percentage agreement between the CergenX Wave result and stage of NE assigned by modified Sarnat examination (i.e. normal/mild abnormality versus moderate/severe abnormality) between 1-6 hours of life
Zeitfenster: From the enrolment and up to 6 hours after birth
|
From the enrolment and up to 6 hours after birth
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in agreement between the modified Sarnat examination and the software-based assessment from the initial assessment (1-6 hours of life) to 24 hours of life (± 6 hours) among infants with initial disagreement.
Zeitfenster: From enrolment of the participant and up to 30 hours after birth
|
From enrolment of the participant and up to 30 hours after birth
|
|
|
Level of agreement between modified Sarnat examination, Wave software, and aEEG/cEEG classification at the same time point in infants with available neurophysiologic monitoring.
Zeitfenster: From enrolment of the participant and up to 30 hours after birth
|
From enrolment of the participant and up to 30 hours after birth
|
|
|
Association between CergenX Wave software and clinical variables including discharge diagnosis
Zeitfenster: From enrolment of the participant and up to 30 hours after birth
|
Discharge diagnoses will be based on the clinical teams ultimate determination, and for analysis will be stratified as perinatal asphyxia without encephalopathy, mild neonatal encephalopathy, moderate encephalopathy, severe encephalopathy or alternate diagnosis. Descriptive statistics will be used to explore the frequency of the output of the Wave device with these diagnoses |
From enrolment of the participant and up to 30 hours after birth
|
|
Assessment of healthcare professional (device users) satisfaction with usability of the device.
Zeitfenster: From enrolment of the participant and up to 30 hours after birth
|
An adapted System Usability Scale (SUS) will be used, referred to as a User Experience Questionnaire that utilises a Likert scale. |
From enrolment of the participant and up to 30 hours after birth
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- 25116
- DT 2023 0435 (Andere Zuschuss-/Finanzierungsnummer: Department of Enterprise, Tourism and Employment. Enterprise Ireland)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .